Breaking Down AmerisourceBergen Corporation Financial Health: Key Insights for Investors

Peeling back the numbers on AmerisourceBergen Corporation (ticker 0HF3.L / ABC), investors will want to note the stock price sitting at $340.93 (change +$0.31 / 0.00%) as of Dec 22, 05:29:32 PST, alongside fiscal 2025 results that include $321.3 billion in consolidated revenue (up 9% year-over-year) driven by $284.96 billion from U.S. Healthcare Solutions and $28.33 billion from International Healthcare Solutions (plus $8.16 billion in Other), adjusted diluted EPS of $16.00 (a 16% increase from $13.76), adjusted operating income of $4.2 billion with a 1.31% margin, and a strong cash position of $4.4 billion with $3.0 billion in adjusted free cash flow; balance-sheet moves include $1.8 billion of senior notes issued in Dec 2024, while the company plans 5-7% revenue growth for fiscal 2026, invests $1 billion in U.S. distribution through 2030 and over $300 million in digital health, and faces persistent risks from drug pricing pressures and limited exposure in emerging markets-read on to unpack what these figures mean for valuation, leverage, liquidity and future upside.

AmerisourceBergen Corporation (0HF3.L) - Revenue Analysis

• Market: USA equity
• Last price: 340.93 USD (change +0.31 USD / 0.00%)
• Latest trade time: Monday, December 22, 05:29:32 PST

• Trailing twelve months (TTM) revenue: 246.3 billion USD
• Year-over-year revenue change: +3.2%
• Revenue split (approx.): Pharmaceutical Distribution ~92%; Global Commercialization Services ~8%

• Volume and product mix: Large share from high-volume pharmaceutical distribution contracts and specialty product launches supporting unit growth.
• Pricing and contract renewals: Modest pricing tailwinds offset by competitive contract negotiations with large health systems and payers.
• Services growth: Global Commercialization Services (manufacturer support, clinical trial logistics) growing faster percentage-wise off a smaller base.
• Seasonality and pandemic effects: COVID-era tailwinds have normalized; recent growth driven by specialty care and oncology product flows.

• Gross margin remains narrow (~4%) due to distributor model; small percentage changes materially impact operating income.
• Operating margin expansion driven by efficiency initiatives, scale in specialty logistics, and cost controls.
• Free cash flow generation has been strong, supporting dividends and debt reduction-FFO/FCF conversion typically high given working-capital management.

• Catalysts: new manufacturer commercialization mandates, increased specialty drug volumes, incremental margin from clinical trial logistics and specialty services.
• Headwinds: reimbursement pressures, margin compression from contract renegotiations, macro volume volatility, and potential regulatory scrutiny on distribution practices.

AmerisourceBergen Corporation (0HF3.L) - Profitability Metrics

• Top-line drivers: U.S. Healthcare Solutions accounted for ~$284.96B (≈88.8% of consolidated revenue); International contributed ~$28.33B (≈8.8%); Other ~ $8.16B (≈2.4%).
• Share count impact: 2.5% reduction in diluted shares supports per-share profitability metrics and EPS leverage from revenue growth.
• Tax profile: a 20.6% adjusted effective tax rate supports near-term adjusted net income stability; FY2026 tax guidance 20%-21%.

Key implications for profitability analysis:

• Revenue growth mix (U.S. outpacing International) suggests continued margin concentration in the U.S. Healthcare Solutions segment.
• Share repurchases (reduced diluted shares) provide EPS accretion even if net income growth moderates.
• Guided FY2026 revenue growth of 5%-7% implies consolidated revenue between approximately $337.4B and $343.8B (using FY2025 base of $321.3B).

For additional context on strategic priorities and corporate direction, see: Mission Statement, Vision, & Core Values (2026) of AmerisourceBergen Corporation.

AmerisourceBergen Corporation (0HF3.L) - Debt vs. Equity Structure

• Adjusted diluted earnings per share (EPS) - FY2025: $16.00; FY2024: $13.76 (16% YoY increase).
• Adjusted operating income - FY2025: $4.2 billion; prior year: ~$3.626 billion (15.8% YoY increase).
• Adjusted operating income margin - FY2025: 1.31%; increase of 7 basis points vs. prior year (prior ~1.24%).
• Adjusted gross profit margin - FY2025: 3.47%.
• Adjusted effective tax rate - FY2025: 20.6%.
• Q4 FY2025 adjusted diluted EPS growth: +15% vs. Q4 prior-year period.

• Profitability drivers: margin expansion (gross and operating), tax efficiency (20.6% effective rate), and EPS leverage from operating income growth.
• Operational leverage: a 15.8% rise in adjusted operating income translated into a 16% increase in adjusted diluted EPS, indicating earnings accretion beyond top-line or base-level profit growth.
• Quarterly momentum: Q4 FY2025 adjusted EPS grew 15% YoY, consistent with fiscal-year improvement.

• Debt vs. equity considerations: with operating income margin at 1.31% and EPS up 16%, investors should review balance-sheet leverage and interest expense sensitivity (noting earnings improvement may help service debt and support buybacks/dividends).
• Capital allocation signal: rising adjusted EPS and operating income suggest capacity for shareholder returns, but evaluate outstanding debt levels, maturities, and covenant terms in the context of modest operating margins.

AmerisourceBergen Corporation (0HF3.L) - Liquidity and Solvency

• December 2024: issued $1.8 billion of senior notes to partially fund the Retina Consultants of America (RCA) acquisition.
• Interest-cost volatility: net interest expense fell in Q1 FY2025 but rose sharply by Q3 FY2025, reflecting new debt and period timing.
• Implication: higher fixed-rate liabilities from the senior notes increase leverage and put upward pressure on interest coverage needs, even as operating cash flows from the RCA deal integration may offset some stress.

• Short-term liquidity considerations: incremental interest service from $1.8B increases cash interest requirements; monitor quarterly interest expense and free cash flow generation for coverage trends.
• Key solvency indicators to watch: interest coverage ratio (EBITDA / net interest), total debt / EBITDA, and near-term maturities tied to the RCA-related issuance.
• Investor-read resources: Exploring AmerisourceBergen Corporation Investor Profile: Who's Buying and Why?

AmerisourceBergen Corporation (0HF3.L) - Valuation Analysis

• Cash balance (FY2025): $4.4 billion
• Adjusted free cash flow (FY2025): $3.0 billion
• Repeatable FCF generation in FY2025: $3.0 billion (reported)

• Strong operating cash generation: $3.0B adjusted FCF provides capital to service debt, fund M&A, buybacks, or dividends.
• Cash runway illustration: with $4.4B cash + $3.0B annual FCF, near-term liquidity flexibility is high even before considering revolving credit or other liquidity sources.
• Valuation implications: persistent $3.0B FCF supports discounted cash flow (DCF) scenarios and improves credit metrics, which can compress WACC and enhance intrinsic value estimates.

AmerisourceBergen Corporation (0HF3.L) - Risk Factors

• Current market price: $340.93 - a reference point for entry, exit, and portfolio weighting decisions.
• Profitability flows through an adjusted effective tax rate of 20.6% for fiscal year 2025, with management guidance expecting a range of 20%-21% for fiscal year 2026.
• Tax-rate stability materially affects after-tax earnings and intrinsic value calculations; the narrow guided range reduces one source of model volatility.
• Regulatory, reimbursement, and litigation exposures are high-impact value risks and should be modeled as probability-weighted adjustments to cash flows.
• Supply-chain and gross-margin pressure scenarios should be stress-tested in any DCF or scenario valuation framework given the company's distribution role.

• Base case: Use current price, FY2026 tax range midpoint (20.5%), stable margins - project modest multiple expansion/contraction relative to peers.
• Downside: Incorporate adverse litigation/regulatory outcomes and a 100-200 bps margin compression - reprice multiple down and apply lower cash-flow outcomes.
• Upside: Margin recovery and modest revenue growth with tax-rate stability near 20% - justify higher terminal multiple and improved free cash flow conversion.

• Start valuation at $340.93 per share and reconcile to enterprise value before adjustments.
• Apply adjusted effective tax rate of 20.6% for FY2025 and model FY2026 tax rate between 20%-21% as sensitivity bands.
• Stress-test for legal and regulatory scenarios with probability-weighted cash-flow impacts.
• Reassess cost of capital and terminal multiple under each scenario to reflect sector and company-specific risk.

AmerisourceBergen Corporation (0HF3.L) - Growth Opportunities

• Scale benefits: top-three global distributor with national pharmacy, specialty, and provider channels enabling pricing and margin optimization.
• Specialty medicines and oncology distribution: faster revenue growth and higher gross margins versus commodity drug distribution.
• Value-added services: provider of sample-to-patient programs, cold-chain logistics, and 340B program support that command premium pricing.
• Strategic partnerships and acquisition runway: potential tuck-ins to expand specialty footprint and biologics handling.
• Margin expansion potential through automation, SKU rationalization, and contract renegotiation with manufacturers and payors.

• The company is exposed to drug pricing pressures that affect profit margins.
• The company has a limited presence in emerging markets compared to competitors.
• The company is exposed to drug pricing pressures that affect profit margins.
• The company has a limited presence in emerging markets compared to competitors.
• The company is exposed to drug pricing pressures that affect profit margins.
• The company has a limited presence in emerging markets compared to competitors.

• Gross margin sensitivity: a 50-basis-point decline in gross margin on $214B revenue reduces gross profit by roughly $1.07B annually.
• Debt service: with ~ $11.5B long-term debt, each 100 bps rise in average borrowing cost increases annual interest expense by ~ $115M.
• Specialty mix: a 5 percentage-point increase in specialty medicine revenue mix (higher gross margin) can materially lift operating margin given current low single-digit margins.

• Specialty revenue as % of total - indicates progress up the value chain.
• Inventory turns - efficiency metric tied to working capital and cash conversion cycle.
• Adjusted EBITDA margin and free cash flow conversion - signal ability to deleverage and invest in automation.